New P2Y12 Inhibitors

[1] Approaching an age of reason with antiplatelet therapy [J]. LANCET, 2008, 371 (9621) : 1315 - 1316

[2] [Anonymous], ADP RECEPTORS ANTAGO

[3] Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) : 1404 - 1411

[4] Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (01) : 5 - 10

[5] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436

[6] Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) : 1844 - 1851

[7] Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (03) : 577 - 582

[8] Conley P, 2006, BLOOD, V108, p270A

[9] The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (07) : 1153 - 1159

[10] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 735 - 741

[1] Approaching an age of reason with antiplatelet therapy [J]. LANCET, 2008, 371 (9621) : 1315 - 1316

[2] [Anonymous], ADP RECEPTORS ANTAGO

[3] Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (14) : 1404 - 1411

[4] Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 103 (01) : 5 - 10

[5] Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (12) : 2429 - 2436

[6] Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) : 1844 - 1851

[7] Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (03) : 577 - 582

[8] Conley P, 2006, BLOOD, V108, p270A

[9] The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (07) : 1153 - 1159

[10] Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 735 - 741